In the latest trading session, 13.53 million Can-Fite Biopharma Ltd ADR (AMEX:CANF) shares changed hands as the company’s beta touched 1.33. With the company’s most recent per share price at $1.52 changed hands at -$0.47 or -23.59% at last look, the market valuation stands at $11.49M. CANF’s current price is a discount, trading about -208.55% off its 52-week high of $4.69. The share price had its 52-week low at $1.87, which suggests the last value was -23.03% down since then. When we look at Can-Fite Biopharma Ltd ADR’s average trading volume, we note the 10-day average is 93130.0 shares, with the 3-month average coming to 102.23K.
Analysts gave the Can-Fite Biopharma Ltd ADR (CANF) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CANF as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Can-Fite Biopharma Ltd ADR’s EPS for the current quarter is expected to be -0.4.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Can-Fite Biopharma Ltd ADR (AMEX:CANF) trade information
Instantly CANF was in red as seen in intraday trades today. With action -25.83%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -30.89%, with the 5-day performance at -25.83% in the red. However, in the 30-day time frame, Can-Fite Biopharma Ltd ADR (AMEX:CANF) is -29.28% down. Looking at the short shares, we see there were 0.14 million shares sold at short interest cover period of 1.66 days.
The consensus price target for the stock as assigned by Wall Street analysts is 10, meaning bulls need an upside of 84.8% from its recent market value. According to analyst projections, CANF’s forecast low is 10 with 10 as the target high. To hit the forecast high, the stock’s price needs a -557.89% plunge from its current level, while the stock would need to soar -557.89% for it to hit the projected low.
Can-Fite Biopharma Ltd ADR (CANF) estimates and forecasts
Data shows that the Can-Fite Biopharma Ltd ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -40.84% over the past 6 months, a 30.17% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach -19.25% down from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 150k. 2 analysts are of the opinion that Can-Fite Biopharma Ltd ADR’s revenue for the current quarter will be 150k. The company’s revenue for the corresponding quarters a year ago was 196k and 196k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -23.47%. The estimates for the next quarter sales put growth at -23.47%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 48.75%. The 2024 estimates are for Can-Fite Biopharma Ltd ADR earnings to increase by 58.37%.
CANF Dividends
Can-Fite Biopharma Ltd ADR is expected to release its next quarterly earnings report in January.
